 |
|
Expanding the Treatment Options for Hepatocellular CarcinomaCombining Transarterial Chemoembolization With Radiofrequency Ablation
Andrew X. Zhu, MD, PhD;
Ghassan K. Abou-Alfa, MD
JAMA. 2008;299(14):1716-1718.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Hepatocellular carcinoma (HCC) represents a challenging malignancy of worldwide importance: it is the sixth most common cancer and the third most common cause of cancer-related death globally.1 The incidence rates for HCC in the United States and Western Europe have been increasing.2-3 Despite many efforts in prevention and screening for HCC, only 20% to 30% of patients present with early stage disease amenable to curative treatments, including surgical resection and liver transplantation.4-5 Although many interventional-based treatment options are available for unresectable HCC, the benefits and limitations of these individual treatment approaches remain controversial.
In this issue of JAMA, Cheng and colleagues6 report their results using combined transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) in a randomized phase 3 trial involving patients with HCC. This important study provides the rationale, safety profiles, and evidence of improved disease control and survival benefits . . . [Full Text of this Article]
Author Affiliations: Massachusetts General Hospital Cancer Center, and Harvard Medical School, Boston, Massachusetts (Dr Zhu); and Memorial Sloan-Kettering Cancer Center, New York, New York (Dr Abou-Alfa).
RELATED ARTICLE
Chemoembolization Combined With Radiofrequency Ablation for Patients With Hepatocellular Carcinoma Larger Than 3 cm: A Randomized Controlled Trial
Bao-Quan Cheng, Chong-Qi Jia, Chun-Tao Liu, Wei Fan, Qing-Liang Wang, Zong-Li Zhang, and Cui-Hua Yi
JAMA. 2008;299(14):1669-1677.
ABSTRACT
| FULL TEXT
|
